It is the first and only non-avian derived hyaluronic acid indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
At the end of a 12-week study, significantly more patients treated with Euflexxa were symptom-free than those treated with Genzyme Corporation’s Synvisc, the leading hyaluronic acid product in its class.
“It is proven to offer better drug-free symptom relief over a 12-week period than the current leading HA therapy. Additionally, it offers proven safety and efficacy with significantly fewer joint effusions and less use of simple analgesics than Synvisc. Not surprisingly, patients reported higher satisfaction with Euflexxa,” said Wayne Anderson, president, Ferring Pharmaceuticals.
In a trial of the drug, 321 patients with confirmed knee osteoarthritis were randomized to treatment with either Euflexxa or Synvisc. At the study endpoint, 63% of patients treated with Euflexxa were symptom-free compared with 52% of those treated with Synvisc.